Scientific Program Highlights
| Cleveland Clinic Advanced Certificate Course In Diabetes 2019 |
|---|
| PLENARY SESSION |
| Many Secret Lives of Adipocytes - Implications for Diabetes |
| STATE OF THE ART LECTURES |
| Lipotoxicity and Beta Cell Maintenance in Obesity and Type 2 Diabetes |
| Managing Dyslipidemia in Diabetes – Changing Paradigms |
| Precision Diabetes – Where do we stand in 2019 |
| New T2Diabetes Therapies on Horizon |
| Gliptins in The Era of GLP1RAs and SGLT2i |
| SCIENTIFIC SESSIONS |
| Hypoglycemia and Cardiovascular Risk – Cause or Just a Marker? |
| Cardiovascular Disease and Diabetic Kidney Disease – What is the Link and What are Therapeutic Targets? |
| The Unique Indian Type 2 Diabetes Phenotype - Therapeutic Implications |
| Advances in Monitoring – SMBG (Conventional Techniques) and Newer Technologies( CGM, AGP, EVERSENS) |
| Dietary Management of Diabetes - Changing Perspectives in Indian Context |
| GLP 1RA and Cardiac Protection |
| SGLT2 Inhibitors and Cardiac Protection |
| Management of Heart Failure in Diabetes Patients – When to Treat, What to Use |
| Is There Really A Difference Between Type 1 and Type 2 Diabetes? |
| Tubulo-glomerular Feedback: Clinical implications |
| SGLT2 Inhibitors and Renal Protection |
| Newer Insulins – Do They Make Difference/Innovations in Insulin Therapy |
| Hospital to Home – Transition Care in Diabetes |
| Vitamin D and Diabetes – Practical Aspects |
| LEARNINGS FROM TRIALS |
| CAROLINA – SUs are CV Safe |
| Reduce-It: Implications in Treatment of Hypertriglyceridemia in Diabetes |
| D2d Study – Vit D and Type 2 Diabetes Study |
| DEBATES |
| Novel Therapies Should Replace Metformin for T2D Management? |
| No! .Metformin Should Remain First Line Drug |
| HYPERTENSION MANAGEMENT |
| Tighter New Guidelines Are Better |
| Older Less Aggressive Guidelines Are Better |
| TRIALS UPDATE |
| CREDENCE |
| New Data from DECLARE TIMI 58 |
| PIONEER |
| RISE |
| EMPRISE |
| REWIND |
| REAL LIFE CASE STUDIES |
WORKSHOPS
Individualizing Therapy in type 2 diabetes: Case based approach –
Insulin Initiation, Intsification and Optimization
Technologies in Diabetes
MEET THE EXPERTS